SCHEMBL7995031

SCHEMBL7995031

CC(C)CC[CH]CCC(C)C

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.35
CA1 P00915 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL423846 0.87 LMNA (0.41) LMNA
SCHEMBL1932322 0.87
SCHEMBL6990184 0.85 LMNA (0.46) LMNA
SCHEMBL380860 0.83 LMNA (0.30) LMNA
SCHEMBL942111 0.83
SCHEMBL2379126 0.83 LMNA (0.32) LMNA
SCHEMBL2999056 0.83 TSHR (0.38) LMNA
SCHEMBL1045278 0.81
SCHEMBL8076785 0.81
SCHEMBL8175475 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6277537-B1 PHENOLIC COMPOUND EASTMAN KODAK COMPANY 2001-08-21 US claimed
US-5512410-A Heat image separation with phenolic thermal solvents and dye releasing couplers EASTMAN KODAK COMPANY (US) 1996-04-30 US claimed
US-11860535-B2 Imprint lithography stamp method of making and using the same KONINKLIJKE PHILIPS N.V. (NL) 2024-01-02 US disclosed
US-11163230-B2 Imprint lithography stamp method of making and using the same KONINKLIJKE PHILIPS N.V. (NL) 2021-11-02 US disclosed
US-20210079167-A1 IMPRINT LITHOGRAPHY STAMP METHOD OF MAKING AND USING THE SAME KONINKLIJKE PHILIPS N.V. (NL) 2021-03-18 US disclosed
US-20200223859-A1 REDUCTION OF ALPHA, BETA-UNSATURATED KETONE LEVELS IN MORPHINAN DERIVATIVE COMPOSITIONS RHODES TECHNOLOGIES (US) 2020-07-16 US disclosed
EP-3440509-B1 IMPRINT LITHOGRAPHY STAMP, METHOD OF MAKING AND USING THE SAME KONINKLIJKE PHILIPS NV (NL) 2020-06-17 EP disclosed
EP-3440509-A1 IMPRINT LITHOGRAPHY STAMP METHOD OF MAKING AND USING THE SAME Koninklijke Philips N.V. (NL) 2019-02-13 EP disclosed
US-20170342084-A1 REDUCTION OF ALPHA, BETA-UNSATURATED KETONE LEVELS IN MORPHINAN DERIVATIVE COMPOSITIONS RHODES TECHNOLOGIES 2017-11-30 US disclosed
WO-2017174755-A1 IMPRINT LITHOGRAPHY STAMP METHOD OF MAKING AND USING THE SAME KONINKLIJKE PHILIPS N.V. (NL) 2017-10-12 WO disclosed
US-6277537-B1 PHENOLIC COMPOUND EASTMAN KODAK COMPANY 2001-08-21 US disclosed
US-6156690-A Solid catalyst component and catalyst for polymerization of olefins TOHO TITANIUM CO., LTD. (JP) 2000-12-05 US disclosed
US-5521039-A NOVEL CHARAGE GENERATING MATERIAL IS DISAZO COMPOUND CONTAINING ALKYNE GROUP FUJI PHOTO FILM CO., LTD. (JP) 1996-05-28 US disclosed
US-5512410-A Heat image separation with phenolic thermal solvents and dye releasing couplers EASTMAN KODAK COMPANY (US) 1996-04-30 US disclosed
US-5356750-A Dye releasing couplers for heat image separation systems EASTMAN KODAK COMPANY (US) 1994-10-18 US disclosed
US-4459300-A ANTIEMETICS, GASTROINTESTINAL DISORDERS, CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS BEECHAM GROUP P.L.C. (GB) 1984-07-10 US disclosed
EP-0069482-A1 Azabicycloalkyl benzamides, process for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1983-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342084-A1 REDUCTION OF ALPHA, BETA-UNSATURATED KETONE LEVELS IN MORPHINAN DERIVATIVE COMPOSITIONS FASN, HSD17B7, DEGS1 LMNA 20/4885CA1 2094/4885
US-20200223859-A1 REDUCTION OF ALPHA, BETA-UNSATURATED KETONE LEVELS IN MORPHINAN DERIVATIVE COMPOSITIONS FASN, HSD17B7, DEGS1 LMNA 20/4885CA1 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.